Takeda Forecasts 7.7% Increase In Operating Profit - Bloomberg

Takeda has made acquisitions, hired executives from overseas, and cut costs in recent years to bolster growth as its best-selling diabetes drug Actos faced cheaper generic rivals. It hired Christophe Weber, a 20-year GlaxoSmithKline Plc (GSK) veteran, in April and plans to name him chief executive next year. For the original version visit http://www.bloomberg.com/news/2014-05-08/takeda-forecasts-7-7-increase-in-operating-profit.html